Aggregate equity premium on shares issued under agreement.

No definition available.

Name:	fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amortization of sub license consideration.

+ References

No definition available.

+ Details

Name:	fate_AmortizationOfSubLicenseConsideration
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Clinical Development Milestone Fees

+ References

No definition available.

+ Details

Name:	fate_ClinicalDevelopmentMilestoneFees
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative arrangement aggregate milestone payments receivable.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative arrangement aggregate payments receivable.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementAggregatePaymentsReceivable
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative arrangement annual payments receivable recorded under deferred revenue.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative arrangement percentage of reduction on milestone payments.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments
Namespace Prefix:	fate_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative arrangement potential additional milestones.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementPotentialAdditionalMilestones
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of upfront payments received under collaborative arrangements is recorded as deferred revenue.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Company Received Payment

+ References

No definition available.

+ Details

Name:	fate_CompanyReceivedPayment
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contra research and development expenses

+ References

No definition available.

+ Details

Name:	fate_ContraResearchAndDevelopmentExpenses
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Corresponding asset for sublicense consideration paid.

+ References

No definition available.

+ Details

Name:	fate_CorrespondingAssetForSublicenseConsiderationPaid
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Enterprise value milestone payment.

+ References

No definition available.

+ Details

Name:	fate_EnterpriseValueMilestonePayment
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Enterprise Value Milestones Liability At Fair Value.

+ References

No definition available.

+ Details

Name:	fate_EnterpriseValueMilestonesLiabilityAtFairValue
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Equity premium on share price per share under agreement.

+ References

No definition available.

+ Details

Name:	fate_EquityPremiumOnSharePricePerShareUnderAgreement
Namespace Prefix:	fate_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone Payment Under Deferred Revenue

+ References

No definition available.

+ Details

Name:	fate_MilestonePaymentUnderDeferredRevenue
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payments during the period.

+ References

No definition available.

+ Details

Name:	fate_MilestonePayments
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Option exercise payment.

+ References

No definition available.

+ Details

Name:	fate_OptionExercisePayment
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Profit loss sharing percentage.

+ References

No definition available.

+ Details

Name:	fate_ProfitLossSharingPercentage
Namespace Prefix:	fate_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Stock issued during period shares for private placement

+ References

No definition available.

+ Details

Name:	fate_StockIssuedDuringPeriodSharesForPrivatePlacement
Namespace Prefix:	fate_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Stock price appreciation milestone payable.

+ References

No definition available.

+ Details

Name:	fate_StockPriceAppreciationMilestonePayable
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Sublicense Consideration Represents an Asset Under ASC, Other Assets and Deferred Costs

+ References

No definition available.

+ Details

Name:	fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Transaction price of agreement.

+ References

No definition available.

+ Details

Name:	fate_TransactionPriceOfAgreement
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront Cash Payment

+ References

No definition available.

+ Details

Name:	fate_UpfrontCashPayment
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront non-refundable non-creditable payment receivable.

+ References

No definition available.

+ Details

Name:	fate_UpfrontNonRefundableNonCreditablePaymentReceivable
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerAssetNetNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

+ Details

Name:	us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of income (expense) related to nonoperating activities, classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_TitleOfIndividualAxis=fate_CandidateTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=fate_CommercialOptionExerciseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=fate_JohnsonJohnsonInnovationJJDCIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	fate_StockPurchaseAgreementAxis=fate_StockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=fate_JanssenBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=fate_UpfrontFeeAndEquityPremiumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fate_JanssenAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=fate_CandidateOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=fate_ResearchServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=fate_CandidateThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=fate_OnoLetterAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fate_SublicenseConsiderationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=fate_AmendedMskccLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions					1 Months Ended			12 Months Ended
	Nov. 07, 2022	Apr. 02, 2020	Sep. 14, 2018	Sep. 14, 2018	May 31, 2024	Jun. 30, 2022	Jun. 30, 2020	Dec. 31, 2024	Dec. 31, 2023	Aug. 31, 2024	Nov. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaboration agreement
Revenue recognized								$ 13,631	$ 63,533
Income expense in change in fair value of the stock price appreciation milestones								24,014	29,583
Candidate 2
Collaboration agreement
Clinical development milestone fees					$ 5,000
Commercial Option Exercise Member
Collaboration agreement
Revenue recognized									10,000
Johnson Johnson Innovation J J D C Inc \| Stock Purchase Agreement
Collaboration agreement
Upfront cash payment		$ 50,000
Company Received Payment		100,000
Equity method investment, underlying equity in net assets		50,000
Issuance of common stock during period for private placements (in shares)							1.8
Common stock per share							$ 28.31
Aggregate purchase price of common stock		$ 50,000
Equity premium per share		$ 9.93
Aggregate equity premium on shares		$ 16,000
Proceeds from private placement of common stock, net of issuance costs		$ 34,000
Janssen Biotech Inc
Collaboration agreement
Collaboration contract asset								17,100
Amortization of sublicense consideration									7,200
Revenue recognized									52,300
Deferred revenue												$ 41,200
Janssen Biotech Inc \| Research And Development
Collaboration agreement
Revenue recognized									11,100
Janssen Biotech Inc \| Upfront Fee and Equity Premium
Collaboration agreement
Revenue recognized									31,200
Janssen Biotech Inc \| Janssen Agreement
Collaboration agreement
Sublicense consideration represents an asset under ASC, other assets and deferred costs								17,100
Ono Pharmaceutical Company Ltd
Collaboration agreement
Transaction price of the agreement				$ 48,000
Non-refundable upfront payments recorded as deferred revenue			$ 10,000
Amortization of sublicense consideration								1,200	0
Revenue recognized								13,600	11,200
Aggregate research and development fees payments receivable			20,000	20,000
Collaborative arrangement potential additional milestones			38,000	38,000
Non-refundable upfront payments recorded as deferred revenue			10,000	10,000
Ono Pharmaceutical Company Ltd \| Candidate 2
Collaboration agreement
Milestone payment under Deferred revenue				10,000
Option exercise payment	$ 12,500
Contra research and development expenses								5,100	8,000
Milestone payments			$ 10,000	10,000
Collaborative arrangement annual payments receivable recorded as deferred revenue				$ 5,000
Ono Pharmaceutical Company Ltd \| Candidate 1
Collaboration agreement
Percentage of reduction on milestone payments			50.00%
Ono Pharmaceutical Company Ltd \| Collaborative Arrangement \| Research services
Collaboration agreement
Revenue recognized								8,600
Ono Pharmaceutical Company Ltd \| Maximum \| Candidate 2
Collaboration agreement
Aggregate milestone payments			$ 843,000
Ono Pharmaceutical Company Ltd \| Maximum \| Candidate 1
Collaboration agreement
Collaborative arrangement potential additional milestones						$ 29,300					$ 30,700
Ono Pharmaceutical Company Ltd \| Maximum \| Candidate 3
Collaboration agreement
Collaborative arrangement potential additional milestones										$ 38,000
Ono Pharmaceutical Company Ltd \| Minimum \| Candidate 1
Collaboration agreement
Profits and losses sharing percentage						50.00%
Collaborative arrangement potential additional milestones						$ 9,300					$ 1,400
Ono Pharmaceutical Company Ltd \| Minimum \| Candidate 3
Collaboration agreement
Collaborative arrangement potential additional milestones										$ 7,300
Ono Pharmaceutical Company Ltd \| Ono Letter Agreement
Collaboration agreement
Milestone payments														$ 10,000
Ono Pharmaceutical Company Ltd \| Ono Letter Agreement \| Collaborative Arrangement \| Research services
Collaboration agreement
Revenue recognized								5,000
Ono Pharmaceutical Company Ltd \| Ono Letter Agreement \| Sublicense Consideration
Collaboration agreement
Sublicense consideration paid								9,000
Amended MSKCC License [Member]
Collaboration agreement
Income expense in change in fair value of the stock price appreciation milestones								800	2,500
Stock price appreciation milestones potential payments								75,000
Stock price appreciation milestone payable													$ 20,000
Enterprise Value Milestones Liability At Fair Value								$ 500	$ 1,300